

10/032403

=> d his

(FILE 'HOME' ENTERED AT 19:11:39 ON 14 JAN 2005)

FILE 'REGISTRY' ENTERED AT 19:11:57 ON 14 JAN 2005

L1 STRUCTURE UPLOADED

L2 8 S L1

L3 1685 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 19:13:13 ON 14 JAN 2005

L4 150 S L3

L5 79 S L4 NOT QUINOLIN?

L6 STRUCTURE UPLOADED

FILE 'REGISTRY' ENTERED AT 19:14:52 ON 14 JAN 2005

L7 50 S L6 SUB=L3 SAMPLE

L8 1503 S L6 SSS FULL SUB=L3

L9 182 S L3 NOT L8


FILE 'CAPLUS' ENTERED AT 19:15:45 ON 14 JAN 2005

L10 4 S L9

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 C,O,S,N

G2 C,S

G3 C,N


Structure attributes must be viewed using STN Express query preparation.

=> d l6

L6 HAS NO ANSWERS

L6 STR

10/032403



G1 C,O,S,N

G2 C,S

Structure attributes must be viewed using STN Express query preparation.

=> d 1-4 bib abs hitstr

L10 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2003:97394 CAPLUS

DN 138:153541

TI Preparation of N-(1,5-naphthyridin-4-yl)piperidine-4-carboxamide derivatives as antibacterial agents

IN Davies, David Thomas; Jones, Graham Elgin; Markwell, Roger Edward; Pearson, Neil David

PA Smithkline Beecham PLC, UK

SO PCT Int. Appl., 97 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003010138	A2	20030206	WO 2002-EP8319	20020725
	WO 2003010138	A3	20031204		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	EP 1419155	A2	20040519	EP 2002-764786	20020725
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
	US 2004198756	A1	20041007	US 2004-484563	20040524
PRAI	GB 2001-18238	A	20010726		
	WO 2002-EP8319	W	20020725		
OS	MARPAT 138:153541				
GI					




I

- AB The title piperidine derivs. [I; one of Z1-Z5 is N, one is CR1a and the remainder are CH, or one or two of Z1-Z5 are independently CR1 a and the remainder are CH; R1, R1a = H, HO, C1-6 alkoxy optionally substituted by (un)substituted C1-6 alkoxy, amino, piperidyl, guanidino or amidino, C1-6 alkoxy-C1-6 alkyl, halo, C1-6 alkyl, C1-6 alkylthio, CF3, CF3O, etc.; R3 = CO2H, C1-6 alkoxycarbonyl, (un)substituted CONH2, cyano, tetrazolyl, (un)substituted 2-oxooxazolidinyl, 3-hydroxy-3-cyclobutene-1,2-dione-4-yl, 2,4-thiazolidinedione-5-yl, tetrazol-5-ylaminocarbonyl, (un)substituted 1,2,4-triazol-5-yl, 5-oxo-1,2,4-oxadiazol-3-yl, (un)substituted C1-4 alkyl or ethenyl, halogen, C1-6 alkylthio, CF3, C1-6 alkoxycarbonyl, C1-6 alkylcarbonyl, C2-6 alkenyloxycarbonyl, C2-6 alkenylcarbonyl, (un)substituted OH or NH2, etc.; R31 is in the 2- or 3-position and is hydrogen or a group listed above for R3, provided that R31 in the 2-position is not optionally substituted hydroxy, amino, trifluoromethyl or halogen; R4 = CH2R51, U-V-R52 (wherein R51 = C4-8 alkyl, hydroxy-C4-8 alkyl, C1-4 alkoxy-C4-8 alkyl, etc.; U = CO, SO2, CH2 and V = (un)substituted CH2; or U = CH2 and V = CO, (un)substituted C(:NOH), SO2; R52 = (un)substituted bicyclic carbocyclic or heterocyclic ring); n = 0,1; AB = (un)substituted NHCO, CONH, COCH2, CH2CO, OCH2, CH2O, NHCH2, CH2NH, NHSO2, CH2 SO2, CH2CH2] and pharmaceutically acceptable derivs. thereof are prepared These compds. are useful in methods of treatment of bacterial infections in mammals, particularly man. Thus, 0.10 g 4-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)-4-methylpiperidine and 0.095 g 2-(3-Oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl methanesulfonate were stirred with 138 mg K2CO3 in 2 mL DMF at room temperature for 3 days to give 4-methyl-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide (II). II oxalate showed min. inhibitory concentration of  $\leq 4$   $\mu$ g/mL against *Staphylococcus aureus* Oxford, *S. aureus* WCUH29, *S. pneumoniae* 1629, *S. pneumoniae* N1387, *S. pneumoniae* ERY 2, *Enterococcus faecalis* I, *E. faecalis* 7, *Haemophilus influenzae* Q1, *H. influenzae* NEMC1, *Moraxella catarrhalis* 1502, and *Escherichia coli* 7623.
- IT 495414-54-5P, 4-(6-Methoxy-[1,5]naphthyridin-4-ylcarbamoyl)-4-methylpiperidine-1-carboxylic acid tert-butyl ester 495414-59-OP, 4-Allyloxycarbonylamino-4-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester 495414-66-9P, 4-Hydroxy-4-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester 495414-76-1P 495414-78-3P, 4-([1,5]Naphthyridin-4-ylcarbamoyl)-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid tert-butyl ester 495414-90-9P 495414-91-OP, 4-Hydroxymethyl-4-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)piperidine-1-carboxylic acid benzyl ester 495414-97-6P, 4-Amino-1-[2-oxo-2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495415-11-7P, 4-Methoxy-4-(6-methoxy-[1,5]naphthyridin-4-ylcarbamoyl)piperidine-1-carboxylic acid tert-butyl ester 495415-20-8P 495415-30-OP 495415-36-6P 495415-42-4P 495415-53-7P, 1-tert-Butoxycarbonyl-4-trifluoromethylpiperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495416-15-4P, 4-Hydroxy-4-[(6-methoxy-[1,5]naphthyridin-4-ylamino)methyl]piperidine-1-carboxylic acid tert-butyl ester
- RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of N-(1,5-naphthyridin-4-yl)piperidine-4-carboxamide derivs. as antibacterial agents)
- RN 495414-54-5 CAPLUS
- CN 1-Piperidinecarboxylic acid, 4-[[[(6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-4-methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


10/032403



RN 495414-59-0 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-4-[[[2-propenyloxy)carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 495414-66-9 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-hydroxy-4-[[[6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 495414-76-1 CAPLUS  
CN 1,4-Piperidinedicarboxylic acid, 4-[[[6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-, 4-(1,1-dimethylethyl) 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)

10/032403




RN 495414-78-3 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-4-[(1,5-naphthyridin-4-ylamino)carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 495414-90-9 CAPLUS


CN 1,4-Piperidinedicarboxylic acid, 4-[[[6-methoxy-1,5-naphthyridin-4-yl]amino]carbonyl]-, 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)



RN 495414-91-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-(hydroxymethyl)-4-[[[6-methoxy-1,5-naphthyridin-4-yl]amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

10/032403




RN 495414-97-6 CAPLUS

CN 4-Piperidinecarboxamide, 4-amino-1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-oxoethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI)  
(CA INDEX NAME)



RN 495415-11-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-methoxy-4-[[[(6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 495415-20-8 CAPLUS

CN 1-Piperidinecarboxylic acid, 3,4-dihydroxy-4-[[[(6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-, 1,1-dimethylethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/032403



RN 495415-30-0 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-hydroxy-3-methoxy-4-[[6-methoxy-1,5-naphthyridin-4-yl]amino]carbonyl]-, 1,1-dimethylethyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 495415-36-6 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-cyano-4-[[6-methoxy-1,5-naphthyridin-4-yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 495415-42-4 CAPLUS


CN 1-Piperidinecarboxylic acid, 4-(aminocarbonyl)-4-[[6-methoxy-1,5-naphthyridin-4-yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

10/032403




RN 495415-53-7 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[6-methoxy-1,5-naphthyridin-4-yl]amino]carbonyl]-4-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI)  
(CA INDEX NAME)



RN 495416-15-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-hydroxy-4-[[[6-methoxy-1,5-naphthyridin-4-yl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 495415-05-9P 495415-06-0P

RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN  
(Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);  
PREP (Preparation); USES (Uses)  
(preparation of N-(1,5-naphthyridin-4-yl)piperidine-4-carboxamide derivs. as




10/032403

antibacterial agents)

RN 495415-05-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2R)-2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 495415-06-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2S)-2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

IT 495415-71-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of N-(1,5-naphthyridin-4-yl)piperidine-4-carboxamide derivs. as antibacterial agents)

RN 495415-71-9 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



IT 495414-52-3P, 4-Methyl-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid

(6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-53-4P  
 495414-56-7P, 4-Amino-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-57-8P 495414-62-5P,  
 1-[2-(Benzo[1,3]dioxol-5-yl)ethyl]-4-hydroxypiperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-63-6P  
 495414-69-2P, 1-[2-(Benzo[1,3]dioxol-5-yl)ethyl]-4-methylpiperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-70-5P 495414-71-6P, 4-Hydroxy-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-72-7P  
 495414-73-8P, 4-(6-Methoxy-[1,5]naphthyridin-4-ylcarbonyl)-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid 495414-84-1P, 4-Hydroxy-1-[2-oxo-2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-85-2P  
 495414-86-3P 495414-87-4P 495414-88-5P, 4-Hydroxymethyl-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-89-6P 495414-93-2P,  
 4-Amino-1-[2-(7-fluoro-3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)-2-hydroxyethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-94-3P 495414-96-5P  
 495414-98-7P, 4-Amino-1-[2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495414-99-8P  
 495415-00-4P, 1-[2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-2-hydroxyethyl]-4-hydroxypiperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495415-01-5P 495415-04-8P  
 495415-07-1P 495415-13-9P, 1-[2-Hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]-4-methoxypiperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495415-14-0P  
 495415-15-1P, 1-[2-(2,3-Dihydrobenzo[1,4]dioxin-6-yl)-2-hydroxyethyl]-4-methoxypiperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495415-16-2P 495415-22-0P  
 495415-23-1P 495415-32-2P 495415-33-3P  
 495415-38-8P, 4-Cyano-1-[2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495415-39-9P 495415-44-6P  
 495415-45-7P 495415-47-9P 495415-48-0P  
 495415-49-1P 495415-55-9P 495415-56-0P  
 495415-57-1P, 1-[2-(2,3-Dihydro-[1,4]dioxino[2,3-c]pyridin-7-yl)ethyl]-4-hydroxypiperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495415-63-9P 495415-69-5P  
 , 6-[2-[4-Hydroxy-4-[2-(6-methoxy-[1,5]naphthyridin-4-yl)ethyl]piperidin-1-yl)ethyl]-4H-benzo[1,4]thiazin-3-one 495415-73-1P,  
 6-[2-[4-Fluoro-4-[2-(6-methoxy-[1,5]naphthyridin-4-yl)ethyl]piperidin-1-yl)ethyl]-4H-benzo[1,4]thiazin-3-one 495415-80-0P  
 495415-81-1P 495415-82-2P 495415-83-3P  
 495415-84-4P 495415-85-5P 495415-86-6P  
 495415-87-7P 495415-88-8P 495415-89-9P  
 495415-90-2P 495415-91-3P 495415-92-4P  
 495415-93-5P 495415-94-6P 495415-95-7P  
 495415-96-8P 495415-97-9P 495416-08-5P  
 495416-09-6P 495416-10-9P 495416-11-0P  
 495416-12-1P 495416-13-2P 495416-14-3P  
 495416-20-1P, 4-Hydroxy-1-[(2R)-2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495416-21-2P,  
 4-Hydroxy-1-[(2S)-2-hydroxy-2-(3-oxo-3,4-dihydro-2H-benzo[1,4]thiazin-6-yl)ethyl]piperidine-4-carboxylic acid (6-methoxy-[1,5]naphthyridin-4-yl)amide 495416-22-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of N-(1,5-naphthyridin-4-yl)piperidine-4-carboxamide derivs. as antibacterial agents)  
 RN 495414-52-3 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-4-methyl- (9CI) (CA INDEX NAME)

10/032403




RN 495414-53-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-4-methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 495414-52-3


CMF C26 H29 N5 O3 S



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 495414-56-7 CAPLUS

CN 4-Piperidinecarboxamide, 4-amino-1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 495414-57-8 CAPLUS


CN 4-Piperidinecarboxamide, 4-amino-1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

10/032403

CM 1

CRN 495414-56-7


CMF C25 H28 N6 O3 S



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 495414-62-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 495414-63-6 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(1,3-benzodioxol-5-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 495414-62-5

CMF C24 H26 N4 O5


10/032403



CM 2


CRN 144-62-7

CME C2 H2 O4



RN 495414-69-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(1,3-benzodioxol-5-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-4-methyl- (9CI) (CA INDEX NAME)



RN 495414-70-5 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(1,3-benzodioxol-5-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-4-methyl-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 495414-69-2

CME C25 H28 N4 O4


10/032403



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 495414-71-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 495414-72-7 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 495414-71-6

CMF C25 H27 N5 O4 S


10/032403



CM 2


CRN 144-62-7

CMF C2 H2 O4




RN 495414-73-8 CAPLUS

CN 4-Piperidinecarboxylic acid, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-4-[[ (6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 495414-84-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-oxoethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 495414-85-2 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-oxoethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 495414-84-1

CMF C25 H25 N5 O5 S


10/032403



CM 2


CRN 144-62-7

CME C2 H2 O4



RN 495414-86-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 495414-87-4 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 495414-86-3

CME C25 H27 N5 O5 S




CM 2




10/032403

CRN 144-62-7  
CMF C2 H2 O4




RN 495414-88-5 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-4-(hydroxymethyl)-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI)  
(CA INDEX NAME)



RN 495414-89-6 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-4-(hydroxymethyl)-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 495414-88-5  
CMF C26 H29 N5 O4 S



CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 495414-93-2 CAPLUS  
CN 4-Piperidinecarboxamide, 4-amino-1-[2-(7-fluoro-3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-

10/032403

(9CI) (CA INDEX NAME)




RN 495414-94-3 CAPLUS

CN 4-Piperidinecarboxamide, 4-amino-1-[2-(7-fluoro-3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 495414-93-2


CMF C25 H27 F N6 O4 S



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 495414-96-5 CAPLUS


CN 4-Piperidinecarboxamide, 4-amino-1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

10/032403




●2 HCl

RN 495414-98-7 CAPLUS  
CN 4-Piperidinecarboxamide, 4-amino-1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-(9CI) (CA INDEX NAME)




RN 495414-99-8 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl


RN 495415-00-4 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-(9CI) (CA INDEX NAME)

10/032403



RN 495415-01-5 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(6,7-dihydro-6-oxo-5H-pyridazino[3,4-b][1,4]thiazin-3-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 495415-04-8 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(6,7-dihydro-6-oxo-5H-pyridazino[3,4-b][1,4]thiazin-3-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



RN 495415-07-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

10/032403




●2 HCl

RN 495415-13-9 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 495415-14-0 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-4-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 495415-15-1 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-4-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)


10/032403



RN 495415-16-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-3,4-dihydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




●2 HCl

RN 495415-22-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-3,4-dihydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, (3S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 495415-23-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-4-hydroxy-3-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


10/032403




●2 HCl

RN 495415-32-2 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-4-hydroxy-3-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 495415-33-3 CAPLUS  
CN 4-Piperidinecarboxamide, 4-cyano-1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 495415-38-8 CAPLUS  
CN 4-Piperidinecarboxamide, 4-cyano-1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)

10/032403




RN 495415-39-9 CAPLUS  
CN 4,4-Piperidinedicarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI)  
(CA INDEX NAME)



●2 HCl


RN 495415-44-6 CAPLUS  
CN 4,4-Piperidinedicarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 495415-45-7 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




10/032403



● 2 HCl

RN 495415-47-9 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)-2-hydroxyethyl]-4-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 495415-48-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)-2-hydroxyethyl]-4-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 495415-49-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(6,7-dihydro-6-oxo-5H-pyridazino[3,4-b][1,4]thiazin-3-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-4-(trifluoromethyl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 495415-55-9 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(6,7-dihydro-6-oxo-5H-pyridazino[3,4-b][1,4]thiazin-3-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-4-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 495415-56-0 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-dioxino[2,3-c]pyridin-7-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 495415-57-1 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-dioxino[2,3-c]pyridin-7-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)


10/032403




RN 495415-63-9 CAPLUS  
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[1-hydroxy-2-[4-hydroxy-4-[2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 495415-69-5 CAPLUS  
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[2-[4-hydroxy-4-[2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)




RN 495415-73-1 CAPLUS  
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[2-[4-fluoro-4-[2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



10/032403

RN 495415-80-0 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 495415-81-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-2-oxo-1H-pyrido[2,3-b][1,4]thiazin-7-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 495415-82-2 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(7-fluoro-3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 495415-83-3 CAPLUS


10/032403

CN 4-Piperidinecarboxamide, 1-[2-(8-acetyl-5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 495415-84-4 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(6,7-dihydro[1,4]dioxino[2,3-d]pyrimidin-2-yl)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 495415-85-5 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(7-bromo-3,4-dihydro-4-methyl-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 495415-86-6 CAPLUS  
CN 4-Piperidinecarboxamide, 4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-1-

10/032403


[2-(2-quinoxaliny)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 495415-87-7 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(7-fluoro-3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 495415-88-8 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-hydroxy-2-([1,2,3]thiadiazolo[5,4-b]pyridin-6-yl)ethyl]-4-methoxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 495415-89-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-(methoxymethoxy)-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 495415-90-2 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)-2-hydroxyethyl]-4-(methoxymethoxy)-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 495415-91-3 CAPLUS  
 CN 4-Piperidinecarboxamide, 4-(acetyloxy)-1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 495415-92-4 CAPLUS  
 CN 4,4'-Piperidinedicarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

10/032403




● 2 HCl

RN 495415-93-5 CAPLUS  
CN 4-Piperidinecarboxamide, 4-amino-1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 495415-94-6 CAPLUS  
CN 4-Piperidinecarboxamide, 4-amino-1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 495415-95-7 CAPLUS  
CN 4-Piperidinecarboxamide, 4-amino-1-[2-(2,3-dihydro-2-oxo-1H-pyrido[2,3-b][1,4]thiazin-7-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)






●2 HCl

RN 495415-96-8 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2Z)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(hydroxyimino)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




●2 HCl

RN 495415-97-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2E)-2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(hydroxyimino)ethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

Double bond geometry as shown.




●2 HCl

RN 495416-08-5 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[2-[4-hydroxy-4-[(6-methoxy-1,5-naphthyridin-4-yl)amino]methyl]-1-piperidiny]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

10/032403




● 2 HCl

RN 495416-09-6 CAPLUS  
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[1-hydroxy-2-[(4-hydroxy-4-[(6-methoxy-1,5-naphthyridin-4-yl)amino]methyl]-1-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 495416-10-9 CAPLUS  
CN 4-Piperidinol, 1-[2-[(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-4-[[[(6-methoxy-1,5-naphthyridin-4-yl)amino]methyl]]-1-hydroxyethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl


RN 495416-11-0 CAPLUS  
CN 2H-1,4-Benzoxazin-3(4H)-one, 6-[1-hydroxy-2-[(4-hydroxy-4-[(2-(6-methoxy-1,5-naphthyridin-4-yl)ethyl)amino]methyl]-1-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)

10/032403




●2 HCl

RN 495416-12-1 CAPLUS  
 CN 4-Piperidinol, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-4-[[[(6-methoxy-1,5-naphthyridin-4-yl)methylamino]methyl]-, dihydrochloride (9CI)  
 (CA INDEX NAME)




●2 HCl

RN 495416-13-2 CAPLUS  
 CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[1-hydroxy-2-[4-hydroxy-4-[[[(6-methoxy-1,5-naphthyridin-4-yl)methylamino]methyl]-1-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)



●2 HCl

RN 495416-14-3 CAPLUS  
 CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[2-[4-hydroxy-4-[[[(6-methoxy-1,5-naphthyridin-4-yl)methylamino]methyl]-1-piperidinyl]ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

RN 495416-20-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2R)-2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 495416-21-2 CAPLUS


CN 4-Piperidinecarboxamide, 1-[(2S)-2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 495416-22-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-pyrido[3,2-b]-1,4-thiazin-6-yl)-2-hydroxyethyl]-4-hydroxy-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



L10 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2002:927429 CAPLUS

DN 138:14011

TI Preparation of bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials

IN Dartois, Catherine Genevieve Yvette; Markwell, Roger Edward; Madler, Guy Marguerite Marie Gerard; Pearson, Neil David

PA Smithkline Beecham P.L.C., UK

SO PCT Int. Appl., 71 pp.



CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
PI	WO 2002096907	A1	20021205	WO 2002-EP5709	20020524	
	W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
	EP 1392686	A1	20040303	EP 2002-774022	20020524	
	R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
	JP 2004534780	T2	20041118	JP 2003-500086	20020524	
	US 2004198755	A1	20041007	US 2004-477900	20040524	
PRAI	GB 2001-12836	A	20010525			
	WO 2002-EP5709	W	20020524			
OS	MARPAT 138:14011					
GI						



AB Piperidine derivs. and pharmaceutically acceptable derivs. [I; wherein one of Z1, Z2, Z3, Z4, Z5 = N, one is CR2 (wherein R2 = H, OH, (C1-C6)alkoxy, etc.) and the remainder are CH, or one of Z1, Z2, Z3, Z4, Z5 = CR2 and the remainder are CH; R3 = H, carboxy, (C1-C6)alkoxycarbonyl, aminocarbonyl, cyano, tetrazolyl, etc.; R4 = U-V-R5, wherein U-V = (CH2)2, CH2CH(OH), CH2CO, and R5 is a (substituted) bicyclic carbocyclic or heterocyclic ring system] were prepared. For example, II was prepared by a multistep synthetic procedure. The prepared compds. are useful in the treatment of bacterial

infections in mammals, particularly man. For example, compound II had MIC values  $\leq 4$   $\mu\text{g/mL}$  against *S. aureus* Oxford.


IT 477786-99-5P 477787-02-3P 477787-05-6P  
 477787-08-9P 477787-11-4P 477787-13-6P  
 477787-16-9P 477787-19-2P 477787-26-1P  
 477787-29-4P 477787-30-7P 477787-32-9P  
 477787-35-2P 477787-36-3P 477787-38-5P  
 477787-39-6P 477787-48-7P 477787-51-2P  
 477788-14-0P 477788-15-1P 477788-17-3P  
 477788-18-4P 477788-19-5P 477788-21-9P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of bicyclic nitrogen-containing heterocyclic derivs. for use as antibacterials)


RN 477786-99-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477787-02-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(1,3-benzodioxol-5-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477787-05-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477787-08-9 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 477787-11-4 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(2,1,3-benzothiadiazol-5-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 477787-13-6 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-3-methyl-2-oxo-6-


10/032403

benzoxazolyl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477787-16-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 477787-19-2 CAPLUS



CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-2-oxo-5-benzoxazolyl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477787-26-1 CAPLUS

CN 4-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-1-[2-(1,3,4,5-tetrahydro-1-oxo-2H-2-benzazepin-2-yl)ethyl]- (9CI) (CA INDEX NAME)





RN 477787-29-4 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-oxoethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477787-30-7 CAPLUS  
 CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-oxoethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1


CRN 477787-29-4  
 CMF C25 H25 N5 O4 S

10/032403




CM 2


CRN 144-62-7  
CMF C2 H2 O4



RN 477787-32-9 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 477787-35-2 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)-2-oxoethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477787-36-3 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)-2-oxoethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 477787-35-2  
CMF C25 H25 N5 O5


10/032403



CM 2


CRN 144-62-7

CMF C2 H2 O4



RN 477787-38-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477787-39-6 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-oxoethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 477787-38-5

CMF C25 H26 N4 O5




CM 2

CRN 144-62-7


CMF C2 H2 O4

10/032403




RN 477787-48-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 477787-51-2 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)



RN 477788-14-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-[(2R)-2-(2,3-dihydro-2-oxo-1H-pyrido[2,3-b][1,4]thiazin-7-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 477788-15-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-[(2S)-2-(2,3-dihydro-2-oxo-1H-pyrido[2,3-b][1,4]thiazin-7-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 477788-17-3 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-dioxino[2,3-c]pyridin-7-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)- (9CI) (CA INDEX NAME)




RN 477788-18-4 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[1-hydroxy-2-[4-[[6-methoxy-1,5-naphthyridin-4-yl]oxy]methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 477788-19-5 CAPLUS

CN 1,5-Naphthyridine, 8-[[1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-4-piperidinyl]methoxy]-2-methoxy- (9CI) (CA INDEX NAME)




RN 477788-21-9 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-2-oxo-1H-pyrido[2,3-

10/032403

b] [1,4]thiazin-7-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-  
(9CI) (CA INDEX NAME)



IT 477787-00-1P 477787-03-4P 477787-06-7P  
477787-09-0P 477787-12-5P 477787-14-7P  
477787-17-0P 477787-20-5P 477787-22-7P  
477787-27-2P 477787-33-0P 477787-41-0P  
477787-43-2P 477787-45-4P 477787-49-8P  
477787-52-3P 477787-54-5P 477787-55-6P  
477787-57-8P 477787-59-0P 477787-61-4P  
477787-62-5P 477788-16-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(preparation of bicyclic nitrogen-containing heterocyclic derivs. for use as  
antibacterials)


RN 477787-00-1 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-  
yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (9CI) (CA  
INDEX NAME)

CM 1

CRN 477786-99-5


CMF C25 H27 N5 O3 S



CM 2

CRN 144-62-7

CMF C2 H2 O4



RN 477787-03-4 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(1,3-benzodioxol-5-yl)ethyl]-N-(6-methoxy-  
1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 477787-02-3

10/032403


CMF C24 H26 N4 O4



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 477787-06-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 477787-05-6


CMF C25 H28 N4 O4



CM 2

CRN 144-62-7

CMF C2 H2 O4




10/032403

RN 477787-09-0 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)


CM 1

CRN 477787-08-9  
CMF C24 H25 F N6 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 477787-12-5 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(2,1,3-benzothiadiazol-5-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 477787-11-4  
CMF C23 H24 N6 O2 S




10/032403



CM 2

CRN 144-62-7

CME C2 H2 O4




RN 477787-14-7 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-3-methyl-2-oxo-6-benzoxazolyl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 477787-13-6


CME C25 H27 N5 O4



CM 2

CRN 144-62-7

CME C2 H2 O4



RN 477787-17-0 CAPLUS


CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 477787-16-9

CME C25 H27 N5 O4


10/032403



CM 2

CRN 144-62-7

CMF C2 H2 O4




RN 477787-20-5 CAPLUS

CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-2-oxo-5-benzoxazolyl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (1:2) (9CI) (CA INDEX NAME)

CM 1

CRN 477787-19-2


CMF C24 H25 N5 O4



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 477787-22-7 CAPLUS

CN 4-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-1-[2-(2-quinoxaliny)ethyl]- (9CI) (CA INDEX NAME)

10/032403




RN 477787-27-2 CAPLUS  
CN 4-Piperidinecarboxamide, N-(6-methoxy-1,5-naphthyridin-4-yl)-1-[2-(1,3,4,5-tetrahydro-1-oxo-2H-2-benzazepin-2-yl)ethyl]-, ethanedioate (9CI) (CA INDEX NAME)


CM 1

CRN 477787-26-1  
CMF C27 H31 N5 O3

PAGE 1-A




PAGE 2-A



CM 2

CRN 144-62-7  
CMF C2 H2 O4




10/032403

RN 477787-33-0 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 477787-32-9  
CMF C25 H27 N5 O4 S




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 477787-41-0 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[(2R)-2-(2,3-dihydro-2-oxo-1H-pyrido[2,3-b][1,4]thiazin-7-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 477787-43-2 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-dioxino[2,3-c]pyridin-7-yl)ethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)

10/032403



●x HCl

RN 477787-45-4 CAPLUS  
CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[1-hydroxy-2-[(6-methoxy-1,5-naphthyridin-4-yl)oxy]methyl]-1-piperidinylethyl-, hydrochloride (9CI)  
(CA INDEX NAME)




●x HCl

RN 477787-49-8 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (salt)  
(9CI) (CA INDEX NAME)

CM 1


CRN 477787-48-7  
CMF C25 H28 N4 O5



CM 2

CRN 144-62-7  
CMF C2 H2 O4


10/032403



RN 477787-52-3 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[2-(3,4-dihydro-3-oxo-2H-1,4-benzoxazin-6-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 477787-51-2  
CMF C25 H27 N5 O5




CM 2

CRN 144-62-7  
CMF C2 H2 O4




RN 477787-54-5 CAPLUS  
CN 4-Piperidinecarboxamide, N-[6-(3-aminopropoxy)-1,5-naphthyridin-4-yl]-1-[2-(4-fluoro-1H-benzimidazol-2-yl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 477787-55-6 CAPLUS


CN 4-Piperidinecarboxamide, N-[6-(3-aminopropoxy)-1,5-naphthyridin-4-yl]-1-[2-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1


CRN 477787-54-5

CMF C26 H30 F N7 O2

PAGE 1-A




PAGE 2-A



CM 2

CRN 76-05-1


CMF C2 H F3 O2



10/032403

RN 477787-57-8 CAPLUS


CN 1,5-Naphthyridine, 8-[[1-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)ethyl]-4-piperidinyl]methoxy]-2-methoxy-, hydrochloride (9CI) (CA INDEX NAME)



● x HCl

RN 477787-59-0 CAPLUS


CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[2-[4-[[[6-methoxy-1,5-naphthyridin-4-yl]oxy]methyl]-1-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



RN 477787-61-4 CAPLUS

CN 3-Piperidineacetic acid, 1-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)methyl]-4-[2-[(6-methoxy-1,5-naphthyridin-4-yl)amino]-2-oxoethyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 477787-62-5 CAPLUS

CN 3-Piperidineacetic acid, 1-[(3,4-dihydro-3-oxo-2H-1,4-benzothiazin-6-yl)methyl]-4-[2-[(6-methoxy-1,5-naphthyridin-4-yl)amino]-2-oxoethyl]-, (3R,4S)-, trifluoroacetate (9CI) (CA INDEX NAME)


CM 1



10/032403


CRN 477787-61-4  
CMF C27 H29 N5 O5 S

Absolute stereochemistry.




CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 477788-16-2 CAPLUS  
CN 4-Piperidinecarboxamide, 1-[(2S)-2-(2,3-dihydro-2-oxo-1H-pyrido[2,3-b][1,4]thiazin-7-yl)-2-hydroxyethyl]-N-(6-methoxy-1,5-naphthyridin-4-yl)-, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

IT 477787-64-7P 477788-05-9P 477788-07-1P  
477788-10-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of bicyclic nitrogen-containing heterocyclic derivs. for use as  
antibacterials)


RN 477787-64-7 CAPLUS  
CN 1-Piperidinecarboxylic acid, 4-[[[(6-methoxy-1,5-naphthyridin-4-yl)amino]carbonyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

10/032403




RN 477788-05-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-([(6-methoxy-1,5-naphthyridin-4-yl)oxy]methyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)





RN 477788-07-1 CAPLUS

CN 2H-1,4-Benzothiazin-3(4H)-one, 6-[[4-([(6-methoxy-1,5-naphthyridin-4-yl)oxy]methyl)-1-piperidinyl]acetyl]- (9CI) (CA INDEX NAME)



RN 477788-10-6 CAPLUS

CN Carbamic acid, [3-[[8-[[[1-[2-(4-fluoro-1H-benzimidazol-2-yl)ethyl]-4-piperidinyl]carbonyl]amino]-1,5-naphthyridin-2-yl]oxy]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2000:260265 CAPLUS  
DN 132:293679  
TI Preparation of naphthyridines and their azaisosteric analogues as  
antibacterials  
IN Hatton, Ian Keith; Pearson, Neil David  
PA Smithkline Beecham P.L.C., UK  
SO PCT Int. Appl., 38 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000021948	A1	20000420	WO 1999-GB3366	19991011
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9961146	A1	20000501	AU 1999-61146	19991011
EP 1127057	A1	20010829	EP 1999-947781	19991011
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002527431	T2	20020827	JP 2000-575854	19991011
US 2003212084	A1	20031113	US 2001-32403	20011220
PRAI GB 1998-22450	A	19981014		
WO 1999-GB3366	W	19991011		
US 2000-807275	B1	20000508		
OS MARPAT 132:293679				

GI




AB The title compds. [I; one of Z1-Z5 = N and the remainder are CH; R1 = H, OH, alkoxy, etc.; either R2 = H, and R3 is in the 2- or 3-position and is H, alkyl, alkenyl, etc.; or R3 is in the 3-position and R2 and R3 together are a divalent :CR6R7 (wherein R6 and R7 = H, alkyl, alkenyl, etc.); R4 = CH2R5 (R5 = alkyl, hydroxyalkyl, alkoxyalkyl, etc.); n = 0-2; A, B = NR8, O, SOx, etc.; x = 0-2; R8 = H, CF3, alkyl, etc.) and their pharmaceutically acceptable derivs., useful in the treatment of bacterial infections in mammals, particularly in man, were prepared E.g., a multi-step synthesis of (3R,4S)-I [Z1-Z4 = CH; Z5 = N; R1 = OMe; A = N(Me); B = CH2; n = 1; R2 = CH:CH2; R3 = H; R4 = n-heptyl] which showed MIC of 0.5 µg/mL against *S. aureus* Oxford, *M. catarrhalis* Ravasio and *S. pneumoniae*, was given.

IT 264232-50-0P 264232-51-1P 264232-52-2P  
264232-53-3P 264232-54-4P 264232-55-5P  
264232-56-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of naphthyridines and their azaisosteric analogs as antibacterials)

RN 264232-50-0 CAPLUS

CN 4-Piperidinecarboxamide, 1-heptyl-N-(6-methoxy-1,5-naphthyridin-4-yl)-  
(9CI) (CA INDEX NAME)



RN 264232-51-1 CAPLUS


CN 4-Piperidinecarboxamide, 1-heptyl-N-(6-methoxy-1,5-naphthyridin-4-yl)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 264232-50-0


CMF C22 H32 N4 O2

10/032403




CM 2

CRN 144-62-7  
CMF C2 H2 O4



RN 264232-52-2 CAPLUS  
CN 4-Piperidineacetamide, 3-ethenyl-1-heptyl-N-(6-methoxy-1,5-naphthyridin-4-yl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 264232-53-3 CAPLUS  
CN 4-Piperidineacetamide, 3-ethenyl-1-heptyl-N-(6-methoxy-1,5-naphthyridin-4-yl)-, (3R,4S)-, ethanedioate (9CI) (CA INDEX NAME)

CM 1

CRN 264232-52-2  
CMF C25 H36 N4 O2

Absolute stereochemistry.


10/032403



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 264232-54-4 CAPLUS

CN 1,5-Naphthyridine-4-ethanol,  $\alpha$ -[[(3R,4S)-3-ethenyl-1-heptyl-4-piperidinyl]methyl]-6-methoxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 264232-55-5 CAPLUS

CN 3,4-Piperidinediacetamide, 1-heptyl-N4-(6-methoxy-1,5-naphthyridin-4-yl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 264232-56-6 CAPLUS

CN 4-Piperidineacetamide, 3-(1,2-dihydroxyethyl)-1-heptyl-N-(6-methoxy-1,5-

10/032403

naphthyridin-4-yl)-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 264232-70-4

RL: RCT (Reactant); RACT (Reactant or reagent)  
(preparation of naphthyridines and their azaisosteric analogs as  
antibacterials)

RN 264232-70-4 CAPLUS

CN 1-Piperidinecarboxylic acid, 3-ethenyl-4-[2-[(6-methoxy-1,5-naphthyridin-4-yl)amino]-2-oxoethyl]-, 1,1-dimethylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 264232-68-0P 264232-69-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of naphthyridines and their azaisosteric analogs as  
antibacterials)

RN 264232-68-0 CAPLUS

CN 3-Piperidineacetic acid, 1-heptyl-4-[2-[(6-methoxy-1,5-naphthyridin-4-yl)amino]-2-oxoethyl]-, 1,1-dimethylethyl ester, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 264232-69-1 CAPLUS

CN 3-Piperidineacetic acid, 1-heptyl-4-[2-[(6-methoxy-1,5-naphthyridin-4-

yl)amino]-2-oxoethyl]-, (3R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2000:133679 CAPLUS  
DN 132:180573  
TI Preparation of imidazopyridine derivatives as TNF and IL-1 production inhibitors  
IN Kato, Hideo; Sakaguchi, Jun; Aoyama, Makoto; Izumi, Tomoyuki; Kato, Ken-ichi  
PA Hokuriku Seiyaku Co., Ltd., Japan  
SO PCT Int. Appl., 111 pp.  
CODEN: PIXXD2  
DT Patent  
LA Japanese  
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000009506	A1	20000224	WO 1999-JP4381	19990812
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000119271	A2	20000425	JP 1999-216125	19990730
TW 533209	B	20030521	TW 1999-88113701	19990811
CA 2339562	AA	20000224	CA 1999-2339562	19990812
AU 9951974	A1	20000306	AU 1999-51974	19990812
AU 744388	B2	20020221		
TR 200100439	T2	20010521	TR 2001-200100439	19990812
EP 1104764	A1	20010606	EP 1999-937053	19990812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9914306	A	20020521	BR 1999-14306	19990812
NZ 509939	A	20020828	NZ 1999-509939	19990812
CZ 292544	B6	20031015	CZ 2001-503	19990812
NO 2001000676	A	20010410	NO 2001-676	20010209
BG 105271	A	20011130	BG 2001-105271	20010219
ZA 2001001452	A	20010917	ZA 2001-1452	20010221
HR 2001000144	A1	20020430	HR 2001-144	20010228
US 6518265	B1	20030211	US 2001-744959	20010502
PRAI JP 1998-241062	A	19980812		
JP 1999-216125	A	19990730		
WO 1999-JP4381	W	19990812		
OS MARPAT 132:180573				
GI				





AB The title compds. I [A1 = (CH<sub>2</sub>)<sub>m</sub>; R1 is hydrogen, hydroxyl, alkyl, cycloalkyl, styryl or aryl; R2 is hydrogen, alkyl, halogeno, hydroxyl, amino, cyclic amino or phenoxy; ring A is an optionally substituted homocycle or heterocycle; R3 is a saturated nitrogenous heterocyclic group; and m is an integer of 0 to 3] are prepared. In an in vitro test using cells, the title compound II.CF<sub>3</sub>CO<sub>2</sub>H at 0.001 μmol gave 79% inhibition of TNF-α production


IT 259180-95-5P 259181-22-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of imidazopyridine derivs. as TNF and IL-1 production inhibitors)


RN 259180-95-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(2-chloro-3-nitro-1,8-naphthyridin-4-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 259181-22-1 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[2-[(3-amino-2-chloro-1,8-naphthyridin-4-yl)amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



10/032403

RE.CNT 17      THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>